• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    test company saurabh

    Emergent BioSolutions

    Aphena Pharma Solutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    test company saurabh

    Syngene

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Meeting Vaccine Requirements

    Modern filling lines to handle PFS for pandemics

    Related CONTENT
    • Vetio Animal Health
    • Prefilled Syringe Manufacturing
    • SGS Completes Phase I Flu Trial
    • WHO Lauds India’s Vaccine Safety
    • Newsmakers: Peter Soelkner
    Dr. David Brett, Vetter Pharma International GmbH11.09.12
    The vaccine market is experiencing a period of renewed interest driven by novel opportunities in areas of unmet need. In the coming years, the pharmaceutical industry is expecting significant growth in the vaccine market segment. But many of the new complex biologic-based vaccines are challenging to produce. Therefore, new solutions are needed to take advantage of this rapidly evolving market. Drug manufacturers can actually benefit from the established know-how and capacities of leading contract development and manufacturing organizations (CMDO) to deliver secure supply for public health.

    For some time, it seemed as if the vaccine market of the typical pediatric and flu vaccines had matured. Recently, however, the segment has been revived due largely to advances in research into the human immune system and pathogenicity. Also, the successful introduction of several new and highly effective vaccines has boosted confidence. Industry analysts like RNCOS expect continuous growth in the coming years. In fact, the RNCOS 2011 Global Vaccine Market Forecast predicts sales growth of almost 20% to about $33 billion by 2013. The best opportunities for drug manufacturers will be in areas such as nosocomial infections, therapeutic vaccines and pandemics.

    But while the outlook is positive, there continue to be a number of challenges ahead. Modern substances that stem from biotechnological processes have more challenging requirements when it comes to production, manufacturing, and administration.  Until recently, the main players had made only limited investment in future technologies in these particular areas. Therefore, to help bridge the technology gap, many pharma firms in the vaccine space are looking into contract manufacturing to take full advantage of the comprehensive know-how and high capacities of leading CDMOs. With their innovative manufacturing facilities, such service providers can realize potential solutions for this emerging growth segment.

    Setting Up a New Premise
    While the established markets for pediatric vaccines and influenza have become increasingly saturated, new biotechnological methods for producing vaccines for complex pathogens like meningitis, hepatitis C, cancer, and HIV are providing new sales growth. The specifications for these substances and their areas of application are giving rise to entirely new packaging and manufacturing processes. Sensitive substances, for example, require extremely high quality and safety standards in production. However, because of the high value of the substances, the trend is to shift away from vials and move towards prefilled syringes. In today’s global world, the risk of pandemics is omnipresent and thus, public vaccination programs are increasingly demanding prefilled syringe use.

    The outbreak of H1N1 in 2009 demonstrated quite well how the lack of speed in vaccine filling could be a potential weak point in effective combat against dangers. In the case of a pandemic, as many as 300 million people in the U.S. alone would need a jab. For the health authorities and emergency management organizations, such numbers represent an enormous challenge. Multi-dose vials need more time and trained personnel for administering the vaccine if accidental “stick” injuries are to be avoided.  As such, many emergency agencies prefer prefilled syringes as an option for vaccinating large numbers of people in a short period of time.

    Looking to the immediate future, vaccine manufacturing plants must be able to produce large quantities within a few weeks while maintaining high quality and safety standards. And because the “blockbuster model” of drug manufacturing is largely in the past, the old monoplant model is no longer relevant or economically feasible. Therefore, today’s CDMOs must be flexible, allowing for a simple product changeover.

    For the pharma company, avoiding loss of expensive antigen is another important issue.  Because they are already meeting stringent requirements to work safely and efficiently for their customers in other areas, CDMOs are in an excellent position to provide answers to this challenge. By collaborating with a top engineering firm, a CDMO can develop a high-speed filling line conceived specifically to meet the complex demands of vaccines.

    A Special Approach for Vaccines
    As the prefilled syringe market becomes more established, pre-sterilized injection systems have now become an accepted alternative to bulk systems. However, the entire process has to be maintained at a high aseptic level — never a simple task. The decisive question is how to introduce the tubs and the syringes into the critical area for filling. For an illustration of what a solution for vaccine filling should look like, let’s look at our newly built high-speed filling line.


    Through collaboration with a leading
    engineering firm, we designed and built an
    innovative and flexible high-speed filling line
    conceived specifically to meet the demands
    of complex compounds like vaccines.
    Because the line utilizes pre-sterilized syringes, the time needed for making preparations at the filling location is considerably lessened. When delivered, the syringes are already washed, siliconized, sterilized and validated and are, therefore, ready for processing. The syringes are nested in magazines and sterile packed in tubs for transportation. The tubs themselves are wrapped in a sterile protective plastic film. Some suppliers even require a second sterile protective film wrap of the tubs.

    To meet quality and safety demands, the line has been equipped with a comprehensive tub-handling concept involving such technical innovations as an automatic disinfection tunnel. To respond to the economic needs, the plant can also perform a number of different filling processes that allow for rapid product changeover. High efficiency is provided thanks to automated processes, optimized paths and a lean operating concept.

    Safe Tub Processing
    The handling of the tubs is the decisive factor in maintaining a high level of quality and safety. That is why tub-maneuvering steps such as unpacking and transportation are performed mechanically and is program-controlled and reproducible. The tubs begin
    their journey in a hygienic and logistics area still wrapped in their protective foil. They are then placed on a conveyor belt that transports them to a class C cleanroom. If the tubs are wrapped in two films, the outer wrapping is removed as the tub passes from the logistics zone to the classified area. While a cutter performs this task automatically, a special tool keeps the film shut until the transfer is completed. Before entering class A, the protective bag is automatically removed and disposed. 


    To aseptically transfer the tubs across
    zones to higher cleanroom classes, a new
    process was developed; although the
    protective bags are cut, they actually stay
    closed until zone transition. This avoids
    contamination entering the bags.
    For tubs with a single wrapping, transportation is directly to the class C room. Thus, all tubs in the classified area are wrapped in a plastic film.

    The packaging is then disinfected in an especially developed automatic spraying tunnel. The wrapping is sprayed with a disinfectant on all sides by means of jets. Any number of products can be used for this step, but alcohol and a sporocide are the preferred method. After spraying, the tubs remain in the tunnel until all the disinfectant has dried. They are then transferred to the crossing point into the filling zone, which is a class A cleanroom. The disinfected wrapping is cut open, but kept closed until the tubs can be introduced so that no contact is made with the remaining wrapping upon entering the higher-classification cleanroom. Only when it reaches the class A environment is the protective lid removed by machine.  The automated process was designed to respond to the issue of how to introduce tubs and syringes aseptically into the classified area.

    Avoiding Errors
    Innovative in-process controls also help contribute to the avoidance of defective filling and ultimately, to greater safety and efficiency. A primary example is the 100% monitoring of all syringes. Prior to filling, each syringe is tested for having the necessary closure parts. An in-line 3-D scanner automatically scans the systems and registers any potential defects. Syringes lacking a closure part are identified and automatically left unfilled. This monitoring system is based on an end-to-end, track-and-trace system with testing and documentation features. Cameras are used to pick up starting data on the number of nested syringes and their formats, and the data is then printed on the tubs. Problems such as the absence of closure parts are automatically noted. The data is assigned directly to the particular syringe in the tub. An inline printer then notes the data on the tub. At the end of the line, a robotic arm automatically removes the syringes from the tub. This process not only prevents loss of substance, but also ensures the sterility of the machine itself by avoiding contamination due to substance leakage from a syringe lacking closure parts.

    Processes That Meet Various Requirements
    Aseptic safe handling of tubs meets one of the main requirements for filling innovative biologics and vaccines. Modern filling plants also have to meet new requirements regarding economic efficiency. This includes creating conditions for manufacturing a variety of substances. Quick and efficient product changeover is necessary because, as mentioned earlier, the blockbuster model is rapidly becoming obsolete and monoplants are no longer economically viable.


    High-speed solution: the filling station with
    as many as 16 filling heads for tubs with 100
    or 160 nested syringes. The newly-built line
    can process units and tubs of various sizes
    and from various manufacturers. Pumping
    systems, such as rotary vane pumps,
    membrane pumps and peristaltic pumps,
    can be adapted, as well as recirculation for
    suspensions. Stoppers can be applied using
    a setting tube or a vacuum process. 
    The production facilities should be able to apply the appropriate processing method for each type of substance. Basically, a line should also be able to fill various syringe systems and formats. Suitable packaging and volumes have to be available to meet differing demands. The line described above allows for the use of tubs with a single or double protective film as well as the pre-sterilized systems that may come from different manufacturers. The plant also has a filling station with as many as 16 filling heads for a variety of formats and quantities of syringes per tub. Tubs with as many as 160 nested syringes can be processed in this manner. The ability to use the appropriate format part for varying sizes also allows for a great deal of flexibility. Different procedures can be selected to install stoppers, so syringes with various silicon layers can be processed as well.

    Furthermore, this plant was designed to integrate several pumping systems in order to meet the demands of various substances. For suspensions, permanent recirculation of the substance in solution is also possible. Thus, one facility offers various options and production conditions for a wide range of different substances. 

    The Key to Flexibility
    One of the decisive issues in selecting a manufacturer is how flexible and quick it is in product changeover. In the case described, this plant uses a restricted access barrier system (RABS), which allows for fast production changes with a high degree of safety. RABS essentially implies stringent separation of user and areas that are in contact with the product. Plastic walls and doors create a physical barrier around the critical zones of the filling area. Ports for gloves are integrated into the barriers to perform the entire manual steps needed for product changeover. The area inside the walls is maintained under cleanroom class A conditions. Laminar flow air travels downward from the ceiling, surrounding the filling machine. The air then leaves the class A area by flowing underneath the barrier into the operating area, which is under class B conditions. From there it is filtered and directed back into the ventilation system.

    During format change and filling, the separating walls must be kept closed. The barrier doors are only opened for cleaning purposes following manufacturing and microbiological monitoring. Line clearance can only be given after a high-level disinfection process is completed with the use of a sporocide. Once these procedures are completed, the gloves are removed and tested for integrity. If they are airtight, they can be sterilized, packed up, autoclaved, and then mounted back into the glove ports in the barriers. Prior to the next production cycle, the change of format can be initiated using the gloves, and without tools. Rapid locks allow for a fast change of parts that can be installed easily through strategically placed glove ports. All the sterilized format parts are brought into the machine using a SteriSet® container. And all parts of the machine or format parts are made of resistant materials that can be autoclaved like stainless steel (316L), PEEK, or silicon. Depending on the product to be filled and conditions on the line, clearance and setup of the line can be achieved within four hours.

    An Efficient Plant
    Short preparation times mean that even in the absence of blockbuster products, modern plants can achieve high capacity utilization. Lines like the one described above can fill several products a day using a 24-hour shift model. Depending on the syringe format and the substance being filled, some products can be manufactured for as long as 20 hours a day. With as many as 16 filling heads, translating to 50,000 syringes per hour, full production output can reach 1 million systems per day. By automatically avoiding filling syringes without closures, the system increases production reliability.

    The plant is especially efficient thanks to its lean servicing concept. Because many processes have been automated, only three staff members are needed to run the line (depending on the situation and momentary requirements). Naturally, the system itself is not the only contributor to high efficiency. The design of the building around the line was also important to enable short paths between various processes such as the compound area and the filling station, permitting the greatest possible utilization of available substance supplies. In sum, reduced preparation times, higher capacity utilization, and leaner servicing resources are conducive to greater optimization of operating and unit costs.

    Overall, the facility described offers the reader in detail how a modern manufacturing line can support the changing demands in prefilled syringe production. They must be flexible and allow for high safety and more efficient production. If these criteria are met, then commercial manufacturing plants will be able to respond to the current and future challenges like cost and competitive pressures, as well as meet the increased regulatory demands in the manufacturing of vaccines and other high-volume products. They will also support drug companies in their efforts to develop innovative therapies and enter growing market segments like vaccines.

    Dr. David Brett is product & service manager at Vetter Pharma International GmbH. He can be reached at 49 751 3700-0.
    Related Searches
    • Filling
    • Vaccine
    • Manufacturing
    • Aseptic
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Prefilled Syringe Manufacturing Prefilled Syringe Manufacturing
    SGS Completes Phase I Flu Trial SGS Completes Phase I Flu Trial
    WHO Lauds India’s Vaccine Safety WHO Lauds India’s Vaccine Safety
    Newsmakers: Peter Soelkner Newsmakers: Peter Soelkner
    Sanofi, MedImmune in RSV Alliance Sanofi, MedImmune in RSV Alliance
    IDT Biologika Establishes Animal Health Biz in U.S. IDT Biologika Establishes Animal Health Biz in U.S.
    SGS Unveils Virus Agent for Clinical Trials SGS Unveils Virus Agent for Clinical Trials
    Vetter Pharma International Vetter Pharma International
    Clinical Manufacturing On Time and Within Budget Clinical Manufacturing On Time and Within Budget
    Vetter continues to expand capacity Vetter continues to expand capacity
    Vetter Development Service Chicago is now ready for realizing clinical syringe projects Vetter Development Service Chicago is now ready for realizing clinical syringe projects
    Vetter Announces Opening of Office to support Growing Asian Healthcare Market Vetter Announces Opening of Office to support Growing Asian Healthcare Market
    IDT Biologika To Expand Viral Vaccine Capacity IDT Biologika To Expand Viral Vaccine Capacity
    India Bolsters Trial Ethics Code India Bolsters Trial Ethics Code

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20


    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20


    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    Trending
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • Catalent Acquires Delphi Genetics
    • Charles River Acquires CDMO Cognate BioServices
    • Spark Therapeutics Appoints CTO
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login